ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

EOLS vs JNJ // GROSS PROFIT MARGIN

Evolus Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: EOLS 1 — JNJ 9
▲ GROSS PROFIT MARGIN LEADER: JNJ
gross-margins
66.30%
gross-margins
67.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EOLS VS. JNJ) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC EOLS JNJ SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE 66.30% 67.90% -1.60 JNJ /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 25.50% -60.50 JNJ /roic <GO>
EV/EBITDA & P/E Valuation — 18.5x — TIE /valuation <GO>
Free Cash Flow Yield -9.20% 2.97% -12.17 JNJ /fcf-yield <GO>
Operating Margin -11.00% 34.70% -45.70 JNJ /operating-margins <GO>
Net Profit Margin -17.40% 28.50% -45.90 JNJ /net-margins <GO>
Revenue Growth (YoY) 11.60% 6.00% +5.60 EOLS /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 5.59 -5.39 JNJ /balance-sheet <GO>
Piotroski F-Score Quality 4/9 8/9 -4.00 JNJ /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 46.1 62.1 -15.97 JNJ /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 1.08 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 23.0x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $496.7M $662.49B -$662.00B JNJ /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR EOLS REV JNJ REV EOLS GROSS % JNJ GROSS % EOLS FCF JNJ FCF
FY 2025 $297.2M $94.19B 66.3% 67.9% -$45.7M $19.70B
FY 2024 $266.3M $88.82B 68.5% 69.1% -$19.5M $19.84B
FY 2023 $202.1M $85.16B — — -$34.0M $18.96B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EOLS // BETA —
JNJ // BETA 1.08